Global Spinal Muscular Atrophy (SMA) Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Spinal Muscular Atrophy (SMA) Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age. There are many types of spinal muscular atrophy that are caused by changes in the same genes. The main methods of SMA include gene therapy and drug therapy.

Market Overview:

The latest research study on the global Spinal Muscular Atrophy (SMA) Treatment market finds that the global Spinal Muscular Atrophy (SMA) Treatment market reached a value of USD 6364.49 million in 2022. It’s expected that the market will achieve USD 12851.67 million by 2028, exhibiting a CAGR of 12.43% during the forecast period.

Market Drivers

The major factors accounting to the growth of the Spinal Muscular Atrophy Treatment Market are growing awareness regarding SMA, its diagnosis and treatment, rise in the government initiatives to improve healthcare infrastructure and increasing R & D activities to develop novel treatment regimen. The increasing awareness in the public regarding SMA and growing number of initiatives to improve the treatment for rare diseases are fueling the market growth of SMA treatment. Emerging treatment therapies in the treatment of SMA is driving the growth of market during the forecast period.

Market Challenges

Spinal Muscular Atrophy (SMA) Treatment belongs to the more cutting-edge medical field. Currently, few products have been approved for marketing, and many products are still in the research and development stage. If there are uncontrollable risks in the development of new products, it will directly lead to the failure of product development. In addition, the market price of products that have been approved for marketing is high, and it is difficult for ordinary patients to bear this medical expense. This limits the promotion of products to a certain extent.

Region Overview:

In 2022, the share of the Spinal Muscular Atrophy (SMA) Treatment market in Europe stood at 43.64%.

Company Overview:

Biogen Idec is one of the major players operating in the Spinal Muscular Atrophy (SMA) Treatment market, holding a share of 60.29% in 2021.

Biogen Idec

Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.

Novartis AG

Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group. Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Novartis's businesses are divided into three operating divisions: Innovative Medicines, Sandoz (generics) and Alcon (eyecare).

Segmentation Overview:

Among different product types, Non-gene therapy segment is anticipated to contribute the largest market share in 2028.

Gene Therapy

SMA gene therapy is a one-time infusion that replaces the defective or missing SMN1 gene with a working copy. This new gene increases survival motor neuron (SMN) protein levels, which improves motor neuron function and increases the likelihood of survival.

Non-gene therapy

Spinal muscular atrophy (SMA) non-gene therapy includes oral small molecule drugs that enhance the expression of SMN protein, muscle activation drugs, neuroprotective drugs, etc.

Application Overview:

In the Spinal Muscular Atrophy (SMA) Treatment market, 54.17% of the total value was generated through the Ambulatory Surgical Centers segment by application in 2022.

Key Companies in the global Spinal Muscular Atrophy (SMA) Treatment market covered in Chapter 3:

Scholar Rock
Cytokinetics, Inc.
Astellas
Biogen Idec
Roche Holding AG
Novartis AG

In Chapter 4 and Chapter 14.2, on the basis of types, the Spinal Muscular Atrophy (SMA) Treatment market from 2018 to 2029 is primarily split into:

Gene Therapy
Non-gene therapy

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Spinal Muscular Atrophy (SMA) Treatment market from 2018 to 2029 covers:

Hospitals
Ambulatory Surgical Centers
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)